Other Briefings
Indian Pharma on Alert as US Slashes Drug Prices Under MFN Policy
On May 12, 2025, the Trump administration mandated pharmaceutical companies to reduce the prices of drugs sold in the US under the MFN pricing model. This could affect the Indian pharma sector, a key supplier to the US market.
India’s Semiconductor Sector: Tracking Government Support and Investment Trends
The Union Cabinet approved the sixth semiconductor unit under the India Semiconductor Mission. We track India’s efforts to facilitate foreign investment into its indigenous semiconductor industry (developing fabs. chip design, ATMP).
Reviewing India’s Economic Pulse Amid Cross-Border Tensions
Despite trade restrictions and cross-border tensions with Pakistan, India’s economy remains resilient—maintaining momentum for domestic manufacturers and continuing to attract foreign investments.
India-Belgium Ties Enter New Era of Defense Manufacturing and Scientific Research
India and Belgium are expanding strategic ties through joint defense ventures, scientific collaboration, and economic diplomacy, with a focus on trade growth, technology transfer, and innovation in space and security sectors.
India-UK FTA Finalized After Three Years of Negotiations
The India–UK FTA, finalized on May 6, 2025, targets implementation in the next 15 months, aiming to enhance trade, reduce tariffs on 90 percent of goods, improve market access, and create jobs in both countries.
India’s M&A Outlook 2025: Domestic Strength and Sectoral Drivers
India Briefing analyzes the 2025 mergers and acquisitions (M&A) landscape, with Q1 seeing 669 deals worth US$29 billion—the highest volume since early 2022.
India’s FTA Network: Updates in 2025
India Briefing shares the latest 2025 update on India’s free trade agreements (FTA). As of May 2, India and the EU aim to conclude FTA talks by the end of 2025, with the next negotiation round set for May 12–16 in New Delhi.
India’s Competition Authority Rolls Out 2025 Cost Regulations Norms
The Competition Commission of India enacts new cost assessment rules under the 2025 regulations to tackle predatory pricing and deep discounting, marking a shift toward sector-neutral oversight.
